Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muthoni Mwaura

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 15, 2021
Constructing confidence: User perspectives on AlereLAM testing for tuberculosisMuthoni Mwaura, Nora Engel
Pathogens (Basel, Switzerland)|May 27, 2023
A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax MalariaArkasha Sadhewa, Sarah Cassidy-Seyoum, Sanjaya Acharya, et al.
BMJ Global Health|June 29, 2026
Risk perceptions of high-dose primaquine and tafenoquine among <i>Plasmodium vivax</i> malaria stakeholders in Ethiopia: a qualitative studyMuthoni Mwaura, Nora Engel, Muhaba Kejela, et al.
Plos One|February 20, 2020
Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and SwazilandMuthoni Mwaura, Kekeletso Kao, Jesse Wambugu, et al.
Journal of Clinical and Translational Science|May 20, 2025
How do study participants want to be informed about study results: Findings from a malaria trial in Cambodia, Ethiopia, Pakistan, and IndonesiaSamuel Alemu Bamboro, Fareeha Abdul Jabbar, Mary Bagita-Vangana, et al.
The Lancet. Infectious Diseases|February 14, 2026
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trialTamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 15, 2021
Constructing confidence: User perspectives on AlereLAM testing for tuberculosisMuthoni Mwaura, Nora Engel
Pathogens (Basel, Switzerland)|May 27, 2023
A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax MalariaArkasha Sadhewa, Sarah Cassidy-Seyoum, Sanjaya Acharya, et al.
BMJ Global Health|June 29, 2026
Risk perceptions of high-dose primaquine and tafenoquine among <i>Plasmodium vivax</i> malaria stakeholders in Ethiopia: a qualitative studyMuthoni Mwaura, Nora Engel, Muhaba Kejela, et al.
Plos One|February 20, 2020
Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and SwazilandMuthoni Mwaura, Kekeletso Kao, Jesse Wambugu, et al.
Journal of Clinical and Translational Science|May 20, 2025
How do study participants want to be informed about study results: Findings from a malaria trial in Cambodia, Ethiopia, Pakistan, and IndonesiaSamuel Alemu Bamboro, Fareeha Abdul Jabbar, Mary Bagita-Vangana, et al.
The Lancet. Infectious Diseases|February 14, 2026
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trialTamiru Shibiru Degaga, Ayodhia Pitaloka Pasaribu, Rupam Tripura, et al.
Pageof 1